Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Larotrectinib sulfate by Bayer for Sarcomas: Likelihood of Approval
Larotrectinib sulfate is under clinical development by Bayer and currently in Phase II for Sarcomas. According to GlobalData, Phase II...
Regorafenib by Bayer for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Regorafenib is under clinical development by Bayer and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...
BAY-2927088 by Bayer for Non-Small Cell Lung Cancer: Likelihood of Approval
BAY-2927088 is under clinical development by Bayer and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Elinzanetant by Bayer for Vasomotor Symptoms of Menopause (Hot Flashes): Likelihood of Approval
Elinzanetant is under clinical development by Bayer and currently in Phase III for Vasomotor Symptoms of Menopause (Hot Flashes). According...
Regorafenib by Bayer for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Regorafenib is under clinical development by Bayer and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According to...
Regorafenib by Bayer for Rhabdomyosarcoma: Likelihood of Approval
Regorafenib is under clinical development by Bayer and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II drugs...
Regorafenib by Bayer for Esophageal Cancer: Likelihood of Approval
Regorafenib is under clinical development by Bayer and currently in Phase III for Esophageal Cancer. According to GlobalData, Phase III...
Regorafenib by Bayer for Gastric Cancer: Likelihood of Approval
Regorafenib is under clinical development by Bayer and currently in Phase III for Gastric Cancer. According to GlobalData, Phase III...
BAY-3018250 by Bayer for Acute Ischemic Stroke: Likelihood of Approval
BAY-3018250 is under clinical development by Bayer and currently in Phase II for Acute Ischemic Stroke. According to GlobalData, Phase...
BAY-2416964 by Bayer for Colorectal Cancer: Likelihood of Approval
BAY-2416964 is under clinical development by Bayer and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
BAY-2416964 by Bayer for Breast Cancer: Likelihood of Approval
BAY-2416964 is under clinical development by Bayer and currently in Phase I for Breast Cancer. According to GlobalData, Phase I...
BAY-2701250 by Bayer for Pulmonary Hypertension: Likelihood of Approval
BAY-2701250 is under clinical development by Bayer and currently in Phase I for Pulmonary Hypertension. According to GlobalData, Phase I...
Emodepside by Bayer for Ancylostomiasis (Hookworm Infections): Likelihood of Approval
Emodepside is under clinical development by Bayer and currently in Phase II for Ancylostomiasis (Hookworm Infections). According to GlobalData, Phase...
BAY-3018250 by Bayer for Pulmonary Embolism: Likelihood of Approval
BAY-3018250 is under clinical development by Bayer and currently in Phase II for Pulmonary Embolism. According to GlobalData, Phase II...
Drug to Inhibit Prolylendopeptidase (PREP) for Chronic Obstructive Pulmonary Disease by Bayer for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
Drug to Inhibit Prolylendopeptidase (PREP) for Chronic Obstructive Pulmonary Disease is under clinical development by Bayer and currently in Phase...
BAY-2416964 by Bayer for Non-Small Cell Lung Cancer: Likelihood of Approval
BAY-2416964 is under clinical development by Bayer and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
Runcaciguat by Bayer for Non-Proliferative Diabetic Retinopathy (NPDR): Likelihood of Approval
Runcaciguat is under clinical development by Bayer and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData,...
BAY-3283142 by Bayer for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
BAY-3283142 is under clinical development by Bayer and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure). According...
BAY-2416964 by Bayer for Pancreatic Cancer: Likelihood of Approval
BAY-2416964 is under clinical development by Bayer and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Bayer's Elinzanetant?
Elinzanetant is a small molecule commercialized by Bayer, with a leading Phase III program in Vasomotor Symptoms of Menopause (Hot...